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Abstract
Gene expression microarrays are the most widely used technique for genome-wide expression profiling. However,
microarrays do not perform well on formalin fixed paraffin embedded tissue (FFPET). Consequently, microarrays cannot be
effectively utilized to perform gene expression profiling on the vast majority of archival tumor samples. To address this
limitation of gene expression microarrays, we designed a novel procedure (39-end sequencing for expression quantification
(3SEQ)) for gene expression profiling from FFPET using next-generation sequencing. We performed gene expression
profiling by 3SEQ and microarray on both frozen tissue and FFPET from two soft tissue tumors (desmoid type fibromatosis
(DTF) and solitary fibrous tumor (SFT)) (total n=23 samples, which were each profiled by at least one of the four platform-
tissue preparation combinations). Analysis of 3SEQ data revealed many genes differentially expressed between the tumor
types (FDR,0.01) on both the frozen tissue (,9.6K genes) and FFPET (,8.1K genes). Analysis of microarray data from frozen
tissue revealed fewer differentially expressed genes (,4.64K), and analysis of microarray data on FFPET revealed very few
(69) differentially expressed genes. Functional gene set analysis of 3SEQ data from both frozen tissue and FFPET identified
biological pathways known to be important in DTF and SFT pathogenesis and suggested several additional candidate
oncogenic pathways in these tumors. These findings demonstrate that 3SEQ is an effective technique for gene expression
profiling from archival tumor samples and may facilitate significant advances in translational cancer research.
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Introduction
The development of gene expression microarrays in the mid-
1990s represented a significant technical achievement that, for the
first time, permitted the systematic genome-wide evaluation of
gene expression [1,2]. Since their introduction, these technologies
have been widely used for gene expression profiling of cancer
samples, leading to the identification of gene expression patterns
that predict the biological and clinical features of a wide range of
human malignancies [3–16].
Despite the large numbers of gene expression profiling
experiments performed on human cancers, the full potential of
these technologies for impacting the clinical management of
cancer patients has not yet been realized [17–21]. A major
limitation of gene expression microarrays for translational cancer
research is that they rely on the availability of fresh frozen tissue
and show inconsistent performance on formalin fixed paraffin
embedded tissue (FFPET) [22–27]. Consequently, gene micro-
arrays cannot be used effectively on the vast majority of tumor
specimens, since few samples are stored frozen. In contrast,
essentially all tumor samples are stored as FFPET in pathology
laboratories around the world [28]. In an attempt to utilize this
rich source of human tumor samples, investigators have resorted to
measuring the expression of relatively small numbers of known
transcripts from FFPET through the use of a variety of targeted
approaches, including reverse transcriptase-polymerase chain
reaction (RT-PCR) [29,30] and cDNA-mediated annealing,
selection, extension and ligation (DASL) [31,32]. No technique
currently exists for accurate quantitative genome-wide expression
profiling from FFPET.
In the past several years, there have been major advances in
sequencing technologies, resulting in the development of ultra
high-throughput sequencing (UHTS) platforms that have allowed
significant increases in sequencing throughput and decreases in
sequencing cost [33,34]. There is considerable hope in the
scientific community that UHTS will overcome the major
limitations of microarray technology and revolutionize the field
of functional genomics [35,36]. UHTS has been developed in
several platforms, including Roche 454, Illumina Genome
Analyzer, and ABI SOLID. These technologies have been used
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binding of transcription factors [39,40] and nucleosomes [41],
characterize genome methylation patterns [42], and have been
recently applied to the sequencing of transcriptomes (RNA-Seq)
[35,36,43–45].
Standard RNA-Seq protocols target the entire gene transcript
by either synthesizing the full-length cDNA using oligo-dT reverse
primers followed by fragmentation of cDNA, or by selecting poly-
A-tailed mRNA followed by RNA fragmentation and cDNA
synthesis using random hexamer oligonucleotides. Since these
techniques attempt to sequence the entire RNA transcript, the
successful application of these methods for expression profiling
depends on the presence of high quality starting total RNA.
No technique currently exists for accurate quantitative genome
wide expression profiling from FFPET in which RNA has been
extensively degraded. We describe here the 3SEQ assay for precise
quantification of genome-wide expression levels on both frozen
tissue and FFPET. In this report, we perform gene expression
profiling on a collection of frozen and FFPET samples from two
soft tissue tumor types (desmoid type fibromatosis (DTF) and
solitary fibrous tumor (SFT)) using both Human Exonic Evidence
Based Oligonucleotide (HEEBO) microarrays (http://microarray.
org/sfgf/heebo.do) and 3SEQ. We assess the performance of these
two gene expression profiling modalities for making reliable gene
expression measurements and for identifying differentially ex-
pressed genes and biological pathways from both frozen tissue and
FFPET.
Results
DTF and SFT Tumor Samples Selected for Gene
Expression Profiling
DTF and SFT are two subtypes of fibroblastic soft tissue tumors,
which show morphologic similarities, but demonstrate distinct
clinical features [46]. The gene expression patterns of DTF and
SFT have been previously studied in our laboratory by microarray
[16,47,48], and these studies have revealed that although DTF
and SFT are both fibroblastic tumors with similar morphologic
features, they show distinct gene expression patterns. These
tumors represent excellent sources of RNA for evaluating a new
gene expression profiling modality, since in contrast to most
carcinomas, DTF and SFT are both composed of a relatively
homogenous population of tumor cells with few contaminating
non-neoplastic cells, resulting in the production of distinct gene
expression patterns.
The current study included a total of 23 samples, which were
each profiled using at least 1 of the 4 platform-tissue type
combinations (3SEQ-frozen, 3SEQ-FFPET, HEEBO-frozen,
HEEBO-FFPET): the HEEBO-frozen analysis included 17
samples (DTF n=9, SFT n=8); the HEEBO-FFPET included
14 samples (DTF n=6, SFT n=8); 3SEQ-frozen included 11
samples (DTF n=5,SFT n=6); and 3SEQ-FFPET included 14
samples (DTF n=6, SFT=8) (Table S1).
3SEQ Sample Preparation and Sequencing
The 3SEQ method is a novel type of RNA-Seq designed for
accurate and quantitative genome wide expression profiling from
both high quality and degraded total RNA by targeting the 39 end
of mRNA. A schematic illustration of the 3SEQ assay is shown in
Figure 1. mRNA is first enriched from total RNA by poly-A
selection to remove the ribosomal RNA and other non-poly-A
RNA. The mRNA from fresh frozen tissue (which is intact and
long) is then fragmented to 100–200 bases. The heat fragmenta-
tion of mRNA is incorporated and combined with the denature
step of 1
st strand cDNA synthesis in the presence of Mg contained
in the 1
st strand cDNA buffer. In contrast, the short mRNA from
FFPET is converted to cDNA directly without any further
fragmentation. The oligo-dt_P7 RT primer used for 1
st strand
cDNA synthesis contains the 25-T P7 sequence at the 59 end. The
double-stranded cDNA is then ligated to the P5 adapter at the 59
end, size selected, and amplified by PCR using primers to P5 and
P7. The resulting directional library is then sequenced from the P5
end using the Illumina Genome Analyzer II.
The primary difference between the 3SEQ protocol described
here and standard RNA-Seq is that standard RNA-Seq attempts
to generate a sequencing library that spans the entire transcript
length. Standard RNA-Seq has been applied to mutation
identification and transcriptional profiling. While sequencing of
the entire transcript provides abundant biological information, a
significant limitation of this technique is it requires high quality
starting RNA. In contrast, the aim of 3SEQ is to perform genome-
wide expression quantification, which can be performed on both
high quality starting RNA as well as degraded RNA. While
standard RNA-Seq targets the entire transcript, 3SEQ creates a
sequencing library with one sequencing primer targeting the poly-
A tail. Therefore, all transcripts amplified during PCR and
incorporated into the sequencing library contain a portion of the
poly-A tail with an upstream sequence of approximately 200 bp in
length. Sequencing is then performed uni-directionally, toward the
poly-A tail. While the priming techniques utilized in standard-
RNA-Seq will typically produce multiple reads per single
transcript (dependent in large part on the transcript length), the
3SEQ protocol is designed to produce a single read per transcript;
therefore, this technique is not susceptible to length-bias, a
problem which significantly complicates attempts at gene
expression profiling using standard RNA-Seq [49]. Performing
appropriate reads-per-gene normalization based on putative
transcript length for transcriptional profiling with standard
RNA-Seq on degraded RNA would be far more difficult than
normalization from high quality starting RNA, since in the setting
of severe RNA degradation putative transcript length is irrelevant;
consequently, the denominator in the reads per kilobase of exon
model per million mapped reads (RPKM) metric, which is a
standard technique for normalization for transcriptional profiling
from RNA-Seq [44], is unknown. 3SEQ, by contrast, gives one
read per transcript molecule, regardless of degradation and
regardless of transcript length. This novel protocol for creating a
directional sequencing cDNA library targeted to a transcript’s 39
end is the primary feature that distinguishes 3SEQ from standard
RNA-Seq and is the feature that allows precise gene expression
profiling from samples with degraded RNA.
Read Mapping, Filtering, and Quantification
For the 3SEQ data, each 25 bp read was mapped to the
genome using Eland. Non-uniquely mapping reads and reads with
.1 mismatch were discarded. Using the final protocol, we
reproducibly obtained just under 50% uniquely mapping reads
(out of the total number of reads that passed the Illumina pipeline
quality filter). The major source of non-uniquely mapping reads
were poly-A sequences, which constituted approximately 20% of
all reads generated by 3SEQ. With improvements in the
sequencing technology and software provided by Illumina
(subsequent to the experiments described in this manuscript), the
total number of reads obtained per 3SEQ run have increased from
,3–6 million in the runs described in this manuscript, to ,10–15
million on our most recent runs. For FFPET samples, an average
of 2 million reads per sample mapped to within 1KB of an
annotated gene on the reference genome, and for frozen samples
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PLoS ONE | www.plosone.org 2 January 2010 | Volume 5 | Issue 1 | e8768Figure 1. 39-end Sequencing for Expression Quantification (3SEQ) schematic. Either intact mRNA from frozen tissue or degraded mRNA
from FFPET is enriched by poly-A selection. The mRNA from frozen tissue is then heat fragmented to approximately 100–200 bases. This heat
fragmentation is incorporated with the RNA heat denature in the 1
st strand cDNA synthesis by including the 1
st strand cDNA buffer which contains
Mg that is required for fragmentation. The short mRNA from FFPET is converted directly to cDNA without fragmentation. The 1
st strand cDNA is
synthesized with an oligo-dT_P7 RT primer that consists of three parts: 25-oligo-dT, P7 sequence linked to oligo-dT at the 59 end and two degenerate
nucleotides NV at the 39 end. The single stranded cDNA is then converted to double stranded cDNA and the P5 linker is ligated to the end of the
cDNA fragment opposite the P7 linker. The linker-ligated cDNA fragments of approximately 250 bp are selected and a PCR reaction is performed with
primers that hybridize to the P5 and P7 linkers. The sequencing library is unidirectional and composed of cDNA, the P7 linker adjacent to the poly-A
tail and the P5 linker on the opposite end of the fragment. The library is sequenced from the P5 end to generate 36 bp reads by a synthesis
procedure using the Illumina Genome Analyzer. The first 25 bp of each read is used to map the reads to the genome. These reads are expected to be
mapped towards to the 39 UTR or the 39 end of the 39-most exon of expressed genes.
doi:10.1371/journal.pone.0008768.g001
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of an annotated gene on the reference genome. For both FFPET
and frozen samples, the highest proportion of annotated reads
mapped to the 39 untranslated region (50% of annotated FFPET
reads and 41% of annotated frozen reads), followed by the coding
exon (14% FFPET and 22% frozen). The remaining reads
mapped to intergenic or intronic regions or mapped with incorrect
orientation. Transcripts that did not map to intragenic regions
with the correct orientation were not included in this analysis. For
each sample, transcripts that mapped uniquely within 1KB of a
gene annotation on the reference genome were attributed to that
gene symbol, leaving ,27K unique genes with at least 1 read
across the 25 sample-preparation type combinations (14 FFPET
and 11 frozen samples) in the 3SEQ analysis. We removed genes
with less than 25 total reads across the samples, leaving ,18K
genes.
For the HEEBO data, the log base 2 of the normalized red/green
ratio was computed for all microarray spots not flagged as low
quality (45,561 HEEBO biosequenceIDs). Multiple probes from the
same HUGO gene ID were averaged, and HUGO gene IDs with
less than 70% valid data were removed, leaving ,24K genes.
All statistical analyses comparing HEEBO with 3SEQ were
limited to the ,12K common genes included in the filtered 3SEQ
and HEEBO data sets. Prior to performing statistical analyses, the
samples were centered by subtracting out the sample mean and
scaled by dividing by the sample standard deviation. The
distribution of the centered and scaled expression values are
provided as Figure S1.
Correlation of Gene Expression Measurements
To compare the ability of 3SEQ and HEEBO to measure gene
expression on FFPET reliably, we computed the Spearman
correlation of the gene expression measurements from frozen
tissue and FFPET for the 7 samples with matched measurements
from both tissue preparations profiled on both 3SEQ and
HEEBO. In all 7 cases, the 3SEQ measurements showed higher
frozen-FFPET correlation than the HEEBO measurements
(Table 1) [mean Spearman rho with 3SEQ=0.76 vs. 0.46 with
HEEBO; Wilcoxon p=0.008]. These findings suggest that 3SEQ
is a more robust platform than HEEBO microarray for gene
expression profiling from FFPET.
The FFPET and frozen samples in our analysis were stored for
varying periods of time prior to RNA extraction. The storage
duration of the FFPET samples ranged from 1 to 8 years, with a
median storage time of 5 years. The frozen samples ranged in
storage time from 0 to 15 years with a median storage time of 4
years. Information on specimen age was unavailable for 4 samples
in the analysis. In our data set, we do not observe any significant
association between storage time of the archival tumor tissue and
the correlation between frozen and FFPET measurements on
either 3SEQ or HEEBO (both p.0.35).
Assessing Differential Gene Expression
A primary goal of gene expression profiling studies in cancer
research is to identify genes differentially expressed between tumor
types [50], and we used this metric as a practical method for
evaluation of the performance of the two platforms. For each gene,
we computed a modified t-statistic in order to quantify the extent
of differential expression between DTF and SFT [51]. We
computed the correlation of the test statistic values obtained from
gene expression profiling on frozen tissue and FFPET for 3SEQ
and HEEBO. This analysis showed a substantially higher
correlation of test statistics generated from frozen tissue and
FFPET on 3SEQ compared with HEEBO (Pearson correla-
tion=0.82 on 3SEQ vs. 0.54 on HEEBO, Figure 2). These
findings suggest that 3SEQ is superior to HEEBO for obtaining
accurate and robust measurements of differential gene expression
from FFPET.
We used permutations to estimate false discovery rates (FDRs)
for the modified t-statistics obtained from the frozen tissue and
FFPET for 3SEQ and HEEBO, as described in [52]. Similar
FDRs were obtained using 3SEQ on frozen tissue and FFPET.
HEEBO microarray resulted in many fewer genes with a low FDR
on FFPET as compared with frozen tissue (Figure 3). Using
FDR,0.01 as a cutpoint, 9,645 genes were identified as
differentially expressed on 3SEQ-frozen, 8,137 on 3SEQ-FFPET,
4,574 on HEEBO-frozen, and only 69 on HEEBO-FFPET
(Figure 3, Table S2). These findings demonstrate that in terms
of identifying differentially-expressed genes with low FDRs, 3SEQ
is far more effective than HEEBO microarray on FFPET.
Different numbers of samples were used for each of the 4
platform-tissue type combinations assessed in the primary analysis
in this study. Importantly, the 3SEQ analyses were performed with
fewer total samples than the HEEBO analyses. Therefore, we
would expect the differential sample sizes to favour HEEBO over
3SEQ. To confirm this hypothesis, we sampled 5 DTF and 6 SFT
from each of the platform-tissue type combinations and repeated
the analysis with equal sample sizes, and as expected, this showed
similar results to those obtained with the full dataset, with a slight
improvement in the performance of 3SEQ relative to HEEBO
(Figure S2).
Agreement of Differentially Expressed Gene Lists
We next assessed the agreement of the lists of genes differentially
expressed between DTF and SFT (FDR,0.01) (Figure 4). 89% of
the genes identified as differentially expressed by 3SEQ on FFPET
were also identified as differentially expressed by 3SEQ on frozen
tissue. 82% of genes identified as differentially expressed by
HEEBO-frozen were also identified as differentially expressed by
either 3SEQ-frozen or 3SEQ-FFPET.
Table 1. Correlation of Gene Expression Profiling
Measurements From Frozen Tissue and FFPET on Matched
Samples.
Sample 3SEQ HEEBO p value
DTF2435 0.81 0.62
DTF2913 0.74 0.58
SFT200 0.41 0.23
SFT3237 0.83 0.64
SFT3524 0.9 0.3
SFT4711 0.85 0.25
SFT4934 0.75 0.57
SFT2162 0.85 N/A
Mean correlation on
matched samples
0.76 0.46 0.008
The table presents the Spearman’s rho statistic as a rank-based measure of
association of gene expression measurements on frozen vs. FFPET. The first 7
samples contained matched frozen and FFPET measurements on both 3SEQ
and HEEBO microarray. The 8th sample contained only matched samples on
3SEQ. The final row of the table shows the mean correlation on matched
samples for 3SEQ and HEEBO with the Wilcoxon test p value to assess the
significance of the observed difference in mean frozen-FFPET correlation on
matched samples profiled with 3SEQ vs. HEEBO.
doi:10.1371/journal.pone.0008768.t001
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To assess the biological significance of the statistically significant
gene lists, we used the DAVID set of bioinformatics resources [53]
to identify the KEGG biological pathways [54] most significantly
enriched in the top 1000 ranked genes with relatively higher
expression in DTF and the top 1000 genes with relatively higher
expression in SFT. Since far fewer than 1000 genes from the
HEEBO-FFPET analysis yielded FDR,0.01, we selected the top
ranked genes with FDR,0.05 for inclusion in the HEEBO-
FFPET gene lists. We performed this analysis separately for each
of the gene lists generated from the differential gene expression
analysis of each of the 4 platform-tissue type combinations (Table
S3 and Table S4).
Biological pathways with relatively increased expression
in DTF. Functional gene set analysis from all 4 platform-tissue
type combinations identified the KEGG pathway ECM-receptor
interaction as relatively enriched inDTF.Thisgene setis comprised
of proteins that function in the interaction of cells with extracellular
matrix, including integrins (ITGB1, ITGB5), collagens (COL1A1,
COL1A2, COL5A1, COL6A2), glycoproteins (FN1, THBS2,
SDC1), and other cell-surface-associated components. DTF is a
fibroblastic neoplasm, so it was not surprising that this gene set,
which contains genes known to be expressed in stromal cells and to
play important roles in regulation of the extracellular matrix, was
highly expressed in DTF. The fact that this pathway was identified
Figure 2. Scatter plot of modified t-statistics on FFPET vs. frozen tissue. Each point is a gene plotted by the t-statistic generated on FFPET
vs. the t-statistic generated on frozen tissue. The black line is a line with a slope of 1 and x intercept at 0, corresponding to perfect correlation
between the axes. The grey dotted line is a plot of the first principal component. The left plot shows the HEEBO data, and the right plot shows the
3SEQ data.
doi:10.1371/journal.pone.0008768.g002
Figure 3. False discovery rate vs. number of genes called
significant. The number of genes called differentially expressed
between DTF and SFT is plotted along the x axis and the corresponding
false discovery rate is plotted along the y axis. The 3SEQ-frozen analysis
includes 5 DTF and 6 SFT; the 3SEQ-FFPET includes 6 DTF and 8 SFT; the
HEEBO-frozen includes 9 DTF and 8 SFT; and the HEEBO-FFPET includes
6 DTF and 8 SFT.
doi:10.1371/journal.pone.0008768.g003
Figure 4. Venn diagram of genes called significant in each
platform-tissue type combination at an FDR,0.01. The orange
circle includes the set of genes identified as differentially expressed by
3SEQ-frozen, the green circle by 3SEQ-FFPET, and the lavender circle by
HEEBO-frozen. Only 69 HEEBO-FFPET genes reached significance at this
threshold, and the HEEBO-FFPET gene list was not plotted in the Venn
diagram. The number of genes and percentage of total genes in each
portion of the Venn diagram are labelled.
doi:10.1371/journal.pone.0008768.g004
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very few genes were identified as differentially expressed on
HEEBO-FFPET, the set of genes identified as highly expressed in
DTF represents a coherent gene set that provides insight into DTF
biology. The Wnt signalling pathway is known to play an important
role in DTF [55–60], and we have previously noted that Wnt
pathway genes show increased expression in DTF, based on
microarray data from frozen tissue [47,48]. 2 Wnt-signalling related
KEGG pathways (Wnt signalling and melanogenesis) were
identified as enriched in DTF only on 3SEQ-frozen and 3SEQ-
FFPET, but not on HEEBO-frozen or HEEBO-FFPET in our
current functional gene set analysis. The re-identification of WNT-
signalling pathways by 3SEQ supports the ability of gene expression
profiling by 3SEQ to identify a key oncogenic pathway in DTF not
only on frozen tissue but also on FFPET.
Several other pathways were identified as relatively highly
expressed in DTF by at least 1 of the platform-tissue type
combinations. 3 of these pathways are closely related to and share
multiple genes in common with the ECM-receptor interaction
pathway (cell communication, focal adhesion, regulation of actin
cytoskeleton). 3 other pathways were identified only on HEEBO-
frozen (glycan structures - biosynthesis 1, axon guidance, adherens
junction) and their significance in DTF must be more fully
evaluated in future studies.
Biological pathways with relatively increased expression
in SFT. Analysis of HEEBO-FFPET data identified no
pathways as enriched in SFT. The KEGG pathway ‘‘prostate
cancer’’ was identified as relatively highly expressed in SFT by
3SEQ-frozen, 3SEQ-FFPET, and HEEBO-frozen. The genes
(FGFR1, BCL2, IGF1, PDGFD, TCF7L2) from this pathway
were identified by all 3 platform-tissue type combinations as highly
expressed in SFT. It has recently been shown that insulin
signalling plays an important role in SFT pathogenesis [61,62].
The ‘‘insulin signalling pathway’’ was identified as significantly
enriched in SFT by both 3SEQ-frozen and 3SEQ-FFPET, but
was not identified as enriched by either HEEBO-frozen or
HEEBO-FFPET. Analysis of 3SEQ data from both fresh tissue
and FFPET revealed several additional biological pathways (acute
myeloid leukemia, VEGF signaling pathway, oxidative
phosphorylation), which are known to play important roles in
oncogenesis in other tumors but whose contribution to SFT
pathogenesis has not previously been described. In addition, a
large set of closely related cancer-associated pathways
(endometrial cancer, non-small cell lung cancer, ErbB signalling,
MAPK signalling, melanoma, GnRH signalling) were identified as
enriched in SFT on the 3SEQ-FFPET data only. These gene sets
share multiple genes in common with each other and with the
‘‘prostate cancer’’ set (including: AKT2, BAD, MAP2K2, PTEN,
AKT3, PIK3R1, CREB3L2, CREBBP, ERBB2, EGFR). These
findings further support the ability of gene expression profiling
by 3SEQ to identify coherent biological pathways that may play
key roles in tumor pathogenesis from both frozen and FFPET.
Identification of Genes Expressed Exclusively (or Almost
Exclusively) in DTF or SFT
DTF and SFT are both fibroblastic neoplasms, which may
represent tumors composed of different stromal cell types or
different pathways of tumor differentiation from a common
stromal cell type. To identify additional diagnostic markers and to
better understand DTF and SFT pathogenesis, it would be useful
to identify genes that show at least low or moderate levels of
expression in DTF or SFT with virtually no expression in the other
tumor type. This type of analysis is very difficult to perform using
expression data from microarrays, since the measurements are
complicated by the presence of background hybridization signal
making it very difficult to confidently identify genes that show an
expression level near zero in either tumor type. In contrast, the
data produced by sequencing is discrete with far less background
noise than microarray data, which greatly facilitates the identifi-
cation of genes expressed in only DTF or SFT (Figure 5). For this
analysis (which we limited to the 3SEQ data), we started with the
,18K genes that showed at least 25 reads across all samples. For
each gene, we computed the fraction of the DTF reads in the full
data set that occur in that gene, and divided this by the fraction of
the SFT reads in the full data set that occur in that gene. A high
score indicates that the gene is highly expressed in DTF relative to
SFT, and a score near zero indicates the opposite. We performed
this analysis separately on both the 3SEQ-frozen and 3SEQ-
FFPET data (Table S5).
18 genes showed either completely exclusive expression in DTF
or at least 100 fold increased expression in DTF compared with
SFT on both the 3SEQ-frozen and 3SEQ-FFPET analyses. This
list includes genes known to be expressed in muscle (MB, MYH7,
TNNI1, TNNT1) and genes involved in development (GJB2,
ACAN, DMRT2, SLC5A1, MYOD1, PAX1). These findings
suggest that a myofibroblastic phenotype including increased
expression of genes involved in developmental processes and
expressed in muscle is specific for DTF compared with SFT. In
addition to known genes, the list includes several poorly
characterized transcripts (C20orf58, DFKZp686J02145), which
may provide new insights into DTF pathogenesis.
44 genes showed either completely exclusive expression in SFT
(with at least 100 total reads across the samples) or at least 100 fold
increased expression in SFT as compared with DTF on both the
3SEQ-frozen and 3SEQ-FFPET analyses. This list includes genes
known to be involved in signal transduction (NPW, GRIA2,
KNDC1, and NRGN), as well as glycoproteins and genes
expressed in the extracellular matrix (PCSK2, FGG, CHGA,
MMP3, SFTPB, PYY). In addition, the list contains several poorly
characterized transcripts (including C1orf92, AB058691, and
LOC126520), which may provide insight into SFT pathogenesis
and serve as candidate novel biomarkers.
Identification of biological pathways enriched in genes
identified as differentially expressed in 3SEQ-frozen but
not 3SEQ-FFPET. To identify biological pathways enriched in
the set of ,2300 genes identified as differentially expressed
(FDR,0.01) on 3SEQ-frozen but not 3SEQ-FFPET, we
performed a functional gene set analysis using DAVID [54],
which showed that the cluster of functional annotation groups
most significantly enriched in this gene set were related to
intracellular signalling, suggesting that transcripts encoding
proteins involved in intracellular signalling may show increased
susceptibility to degradation in FFPET.
Discussion
Since the introduction of gene expression microarrays in the
mid-1990s, genome-wide expression profiling has been widely
utilized in cancer research [63,64]. Gene expression profiling
experiments have led to significant advances in our understanding
of a wide range of human malignancies, but clinical research
efforts have been frustrated by lack of specimens. A major
hindrance to the translation of gene expression profiling to the
clinic is the fact that gene expression microarrays are best
performed on fresh frozen tissue, and few samples are stored as
fresh frozen. In contrast, essentially all tumor specimens are stored
as FFPET [28]. This fixation and storage technique results in
extensive RNA fragmentation [29]. Several groups have attempt-
3SEQ for Expression Profiling
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8768Figure 5. 3SEQ reads visualized on the UCSC Genome Browser. The top portion of panels A and B show an ideogram of chromosome 20 with
a vertical red bar at cytoband 20q13.33. A small portion of this cytoband is expanded and displays four custom tracks beneath it: DTF2435-FFPET,
DTF2435-Frozen, SFT3524-FFPET, and SFT3524-Frozen. Each of these tracks displays the 3SEQ sequencing reads from a single DTF sample (DTF2435)
and a single SFT sample (SFT3524), whose gene expression was measured from both FFPET and frozen tissue. Each track displays a red or blue block
indicating a 3SEQ read that mapped to the displayed portion of the genome. The blocks are colored according to the read’s directionality with reads
aligned to the genome in the forward (left to right) direction in blue and reads aligned to the genome in the reverse orientation in red. In panel a, two
adjacent genes are displayed on the bottom of the panel with the gene on the left (BIRC7) oriented 59 to 39 from left to right, and the gene on the
right (NKAIN4/C20orf58) oriented 59 to 39 from the right to left. Panel a shows that NKAIN4 is expressed at a moderate level exclusively in DTF (both
FFPET and frozen), while BIRC7 shows a total of 4 reads exclusively in the SFT sample (both FFPET and frozen) with no reads in the DTF sample. In this
example, all reads mapped with the correct orientation to the 39 portion of the transcript. Panel B shows a higher magnification display of a nearby
region on 20q13.33. This genomic region encodes a transcript (AK025855/AK092092) that is expressed exclusively in SFT3524 (FFPET and Frozen) with
no expression in DTF2435. Beneath the display of the piles of reads at the 39 end of the transcript, a higher magnification view of the actual read
sequences from a portion of the pile is displayed.
doi:10.1371/journal.pone.0008768.g005
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[22–27] with mixed results. Difficulties of gene expression profiling
by microarray on FFPET include the inability to obtain adequate
RNA for gene microarray profiling from most archival samples
[25] and a lack of sensitivity for identifying genes known to be
expressed from frozen tissue in matched FFPET samples [26].
Due to the difficulty of gene expression profiling from FFPET
using microarrays, several groups have utilized RT-PCR to
quantify the expression of targeted sets of genes [29,30,65].
Recently, Hoshida et al. performed DASL for gene expression
profiling from FFPET and identified a gene expression pattern
that correlates with survival in hepatocellular carcinoma [31];
however, this study does not demonstrate the ability for full
unbiased genome-wide expression profiling from FFPET, as the
analysis was limited to only 6,100 genes targeted by the probe set.
3SEQ is sequencing-based and overcomes the major limitations
of hybridization-based expression arrays, allowing more sensitive
and precise quantitative measurements for genome-wide expres-
sion profiling. The primary feature that differentiates the 3SEQ
protocol from standard RNA-Seq protocols is that while standard
RNA-Seq typically generates a non-directional sequencing library
comprised of fragments of RNA that span the transcript length,
the 3SEQ protocol generates a directional sequencing library
comprised predominantly of ,200 bp cDNA fragments with a
poly-A tail, in which sequencing will proceed directionally toward
the poly-A tail. This novel design is essential for performing
accurate transcriptional profiling from severely degraded RNA,
because it ensures that one read per transcript molecule is
produced, regardless of degradation and regardless of transcript
length.
Compared to other existing gene expression profiling methods,
the 3SEQ method facilitates gene expression profiling of degraded
RNA from FFPET. In the current study, we identified similar
numbers of differentially expressed genes between DTF and SFT
on frozen tissue (,9.6K) and FFPET (,8.1K) by 3SEQ. In
contrast, we identified fewer differentially expressed genes on
frozen tissue (,4.6K) and far fewer genes on FFPET (only 69
genes) by HEEBO microarray. These data clearly indicate that, in
contrast to HEEBO microarray, 3SEQ is effective for genome-
wide gene expression profiling on both frozen tissue and FFPET,
with similar performance on the two tissue types.
Functional gene set analysis of 3SEQ data from frozen tissue
and FFPET revealed two key sets of pathways (Wnt signalling-
related pathways, and extracellular matrix-related pathways) to be
enriched in DTF. HEEBO analysis identified the extracellular
matrix-related pathways, but failed to identify significant enrich-
ment in the Wnt signalling pathways, which are known to play a
critical role in DTF [55–60]. In addition, functional gene set
analysis of genes with relatively increased expression in SFT by
3SEQ identified insulin signalling as a significantly enriched
pathway and recent studies suggest that insulin receptor activation
is frequently seen in SFT [61,62]. Analysis of 3SEQ data from
both frozen tissue and FFPET revealed several related cancer-
associated pathways (prostate cancer, VEGF signalling, acute
myeloid leukemia) containing a number of genes known to be
important in carcinogenesis (AKT2, IGF1, BAD, PIK3R1,
CCND1, PML, RARA), whose concerted role in SFT has not
previously been characterized. There were no pathways identified
by HEEBO-FFPET as enriched in SFT. These findings further
suggest that 3SEQ is superior to HEEBO microarray for gene
expression profiling from FFPET.
An additional advantage of 3SEQ data is that it can be utilized
to identify genes expressed in at least low or moderate levels in one
of the tumor types with virtually no expression in the other tumor
type. This type of quantitative analysis, which is very difficult to
perform on microarray data due to background noise and
hybridization artefacts, may facilitate a deeper understanding of
differential pathways of tumor pathogenesis and the identification
of highly specific diagnostic markers.
These findings have significant implications for translational
cancer research. A major goal of translational cancer research is to
identify diagnostic markers, prognostic markers, and markers to
predict response to treatment. Each of these goals requires the
acquisition of large numbers of well-annotated clinical specimens
with long term follow-up [19]. The lack of adequate samples with
detailed clinical information (such as drug response) has been a
major impediment to the translation of gene expression profiling
findings to the clinic [18]. We believe 3SEQ could revolutionize
the field of translational cancer genomics, by allowing investigators
to perform gene expression profiling on large numbers of well-
annotated archival tumor specimens with long term follow-up.
Experiments could then be designed to identify gene expression
signatures to predict specific clinically important phenotypes (such
as drug response, progression/recurrence risk, and survival) and to
gain a deeper understanding of cancer biology.
Methods
Ethics Statement
The soft tissue tumors were collected using HIPAA compliant
Stanford University Medical Center institutional review board
approved written informed consent. Some of the tissues already
existed in tissue banks and fall under exemption 4.
Tumor Samples
The study included a total of 23 samples, which were profiled
using at least one of the 4 platform-tissue type combinations
(3SEQ-frozen, 3SEQ-FFPET, HEEBO-frozen, HEEBO-FFPET)
(Table S1). Overall, the HEEBO-frozen analysis contained 17
samples (DTF n=9, SFT n=8), the HEEBO-FFPET contained
14 samples (DTF n=6,SFT n=8), 3SEQ-frozen contained 11
samples (DTF n=5,SFT n=6), and 3SEQ-FFPET contained 14
samples (DTF n=6, SFT=8). The archival samples used in all
analyses were collected from 2000–2007. All cases represented
classic examples of sporadic type DTF and benign SFT.
Additional information on the tumors is provided in Table S1.
RNA Preparation
For total RNA extraction from frozen tissue stored at 280uC,
tissue was homogenized in Trizol reagent (GibcoBRL/Invitrogen,
Carlsbad, USA, CAT#15596-018) and total RNA was prepared.
For total RNA extraction from FFPET, multiple 20 mm sections
were cut from each paraffin block and deparaffinised using xylene
and ethanol. A protease digestion was then performed prior to
nucleic acid isolation, nuclease digestion, and final RNA
purification (Recover All Total Nucleic Acid Isolation kit, Ambion
CAT#AM1975).
Labeling and Hybridization to HEEBO Microarrays
Prior to labelling, the total RNA from frozen samples used for
the HEEBO microarray was subject to a DNAse treatment
(Qiagen RNAse-Free DNAse Set) and RNA clean-up procedure
(RNeasy Mini Kit). The total RNA extracted from FFPET was
amplified using a procedure described elsewhere [66]. The
HEEBO microarrays contain 44,544 70-mer probes designed
using a transcriptome-based annotation of genomic loci (http://
www.microarray.org/sfgf/heebo.do). We performed: indirect la-
belling of the tumor total RNA-derived cDNA (Cy5) and reference
3SEQ for Expression Profiling
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ing; and scanning with GenePix 4000 microarray scanner and
GenePix software as previously described [67]. All microarray
data is MIAME compliant and the raw data has been deposited in
the Stanford Microarray Database (http://smd.stanford.edu/) and
the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo/) with accession number GSE18209.
Generation of 3SEQ Sequencing Library
mRNA was isolated from 10 mg of total RNA extracted from
either frozen tissue or FFPET by polyA selection using Oligotex
mRNA Kit (Qiagen). For mRNA from frozen tissue, RNA heat
fragmentationwascombinedwithheatdenatureincDNAsynthesis:
9 ml of mRNA wasfragmented to 100–200 bases byincubationwith
4 ml of First Strand Buffer and 1 mlo f1 0 0mM oligo-dT_P7 RT
primer at 85uC for 10 minutes; RNA fragmentationwas assessed by
gel electrophoresis; the mixture was then cooled down to 50uC and
followed by the 1
st strand cDNA synthesis in 20 ml reaction with
Superscript III Reverse Transcriptase (Invitrogen) for 1 hour at
50uC; the 1
st strand cDNA was then converted to double-stranded
cDNA and end repaired as described by the manufacture. The
mRNA from FFPET was converted directly to cDNA without any
fragmentation using the procedure as described above for frozen
tissue with the exception that the 4 ml of First Strand Buffer was
added to the reaction after the 85uC denature step and the reaction
has been cooled down to 50uC. After purification with Qiagen
MinElute Kit, the cDNA was ligated to double-stranded P5 Linker
(1 mlo f1 0 0mM) overnight at 16uC. The linker-ligated cDNA was
purified and size selected for 200–300 bp fragment by agarose gel
fractionation. The selected linker-ligated cDNA contains P7
sequence at the 39 end immediately downstream of poly A and
P5 at the 59 end. The final library was generated by PCR
amplification of the Linker-ligated cDNA with two primers of P5
andP7andPhusionPCRMasterMix(NewEnglandBiolab)usinga
15 cycle program (98uC for 30 sec; 15 cycles of 98uC for 10 sec,
65uC for 30 sec, 72uC for 30 sec; 72uC for 5 min).
Sequencing and Read Mapping on the Genome
Following generation of the sequencing library, sequencing was
performed using the Illumina Genome Analyzer II.
Gene Filtering, Scaling, and Quantification
For the HEEBO data, the log base 2 of the normalized red/green
ratio was computed for all microarray spots not flagged as low
quality (45,561 HEEBO biosequenceIDs). Multiple probes from the
same HUGO gene ID were averaged, and HUGO gene IDs with
less than 70% valid data were removed, leaving ,24K genes.
For the 3SEQ data, each 25 bp read was mapped to the
genome (Hg18) using Eland software, provided by Solexa. Non-
unique hits and hits with .1 mismatch were discarded. For each
sample, the sum of the unique annotated hits located within 1KB
of a gene annotation on the reference genome was computed,
leaving ,27K genes with at least 1 hit. We removed genes with
less than 25 total hits across 25 samples, leaving ,18K genes.
Statistical analyses comparing 3SEQ and HEEBO were limited
to the ,12K genes included in the filtered 3SEQ data set and
present on the HEEBO microarray platform.
Statistical Analysis
Data centering and scaling. All samples were centered by
subtracting the sample mean and scaled by dividing by the sample
standard deviation. All statistical analyses comparing 3SEQ and
HEEBO were performed separately on the scaled measurements
from the 4 platform-tissue preparation combinations (3SEQ-
frozen, 3SEQ-FFPET, HEEBO-frozen, HEEBO-FFPET).
Correlation of gene expression measurements. To assess
the correlation of gene expression measurements from frozen tissue
and FFPET on 3SEQ and HEEBO, we computed Spearman’s rho
as a rank-based non-parametric measure of correlation. To assess
the correlation of the test statistics generated on frozen tissue and
FFPET, we computed the Pearson’s correlation of the test statistics
on each of the platforms.
Significance testing: Significance testing was performed using
modified two-sample t-statistics in order to identify genes
differentially expressed between DTF and SFT. FDRs were
estimated by permutations. The modified t-statistic was computed
as described in [51] as: d(i)~
  x xSFT(i){  x xDTF(i)
s(i)zs0
, where   x xSFT(i)
and   x xDTF(i) are defined as the average expression levels for gene i
in SFT and DTF respectively, s0 is a small positive constant, which
we set to 0.05, and s(i) is the standard deviation of repeated
expression measurements. To generate an FDR for symmetric cut-
offs of the test statistics, we: permuted the sample class labels for
150 iterations; computed a modified t-statistic (as described above)
for each gene during each iteration; and calculated the FDR for
test statistic c as:
median over the permuted data sets of nperm(abs(t)§abs(c))
 
nreal(abs(t)§abs(c))
, where nperm(abs(t)§abs(c)) is the number of genes in each permuted
dataset with a t-statistic greater than or equal to c in absolute value,
and nreal(abs(t)§abs(c)) is the number of genes in the real dataset with
a t-statistic greater than or equal to c in absolute value.
Functional gene set analysis. Functional gene set analysis
was performed using the DAVID set of bioinformatics tools
[53,68]. For the gene set analysis, we ranked the genes by test
statistic and submitted the top 1000 genes in DTF and SFT for
3SEQ-frozen, 3SEQ-FFPET, and HEEBO-frozen. For HEEBO-
FFPET we submitted the genes relatively highly expressed in DTF
(114 genes) and SFT (57 genes) with an FDR,0.05. We identified
the KEGG pathways containing at least 10 genes from the
submitted gene list with a modified Fisher exact p value (EASE
score [53]) less than 0.05.
Supporting Information
Figure S1 Histograms of probability density of scaled and
centered expression values. (A) 3SEQ-FFPET; (B) 3SEQ-frozen;
(C) HEEBO-FFPET; and (D) HEEBO-frozen. The x axis is the
scaled expression value. The y axis is the histogram density.
Found at: doi:10.1371/journal.pone.0008768.s001 (0.34 MB TIF)
Figure S2 False discovery rate vs. number of genes called
significant with equal sample sizes. Since our dataset contained
slightly different numbers of samples in each platform-tissue type
combination (Table S1), we performed the FDR vs. genes called
significant analysis with all platform-tissue type combinations
containing 5 DTF vs. 6 SFT samples. For this analysis, we
performed 50 iterations, in which we selected 5 DTF and 6 SFT
samples from each platform-tissue type combination. We then
took the mean and median of the results across the 50 iterations.
The mean (A) and median (B) results with equal sample sizes of the
FDR vs. number of genes differentially expressed plots are
displayed.
Found at: doi:10.1371/journal.pone.0008768.s002 (0.99 MB TIF)
Table S1 DTF and SFT tumor samples included in the analysis.
The table lists the 23 sample IDs in the first column. The next 3
3SEQ for Expression Profiling
PLoS ONE | www.plosone.org 9 January 2010 | Volume 5 | Issue 1 | e8768columns list the tumor resection year, RNA extraction year, and
RNA yield, respectively. The final 4 columns are labelled 3SEQ-
FFPET, 3SEQ-Frozen, HEEBO-FFPET, and HEEBO-Frozen,
respectively. A cell contains an ‘‘X’’ if the row’s sample was
profiled by the platform-tissue type combination indicated by the
column’s header.
Found at: doi:10.1371/journal.pone.0008768.s003 (0.06 MB
DOC)
Table S2 Test statistics and FDRs. The first column indicates
the gene symbol for the 12,512 genes included in the analysis. The
next 8 columns display the row’s gene’s modified t-statistic and
FDR obtained by 3SEQ-frozen, 3SEQ-FFPET, HEEBO-frozen,
and HEEBO-FFPET, respectively. A negative t-statistic indicates
that the gene showed relatively higher expression in DTF, and a
positive t-statistic indicates that the gene showed relatively higher
expression in SFT.
Found at: doi:10.1371/journal.pone.0008768.s004 (2.37 MB
XLS)
Table S3 Summary of results from functional gene set analysis.
All 25 KEGG gene sets that showed relative enrichment in either
DTF or SFT by 1 of the 4 platform-tissue type combinations is
indicated in the first column. The next 8 columns contain an ‘‘X’’
if the row’s KEGG biological pathway was identified as relatively
enriched in DTF (columns B–E) or SFT (columns F–I) by analysis
on 3SEQ-frozen (columns B and F), 3SEQ-FFPET (columns C
and G), HEEBO-frozen (columns D and H), and HEEBO-FFPET
(columns E and I).
Found at: doi:10.1371/journal.pone.0008768.s005 (0.06 MB
DOC)
Table S4 Detailed results of functional gene set analysis. This
table displays separately the results from 3SEQ-frozen, 3SEQ-
FFPET, HEEBO-frozen, and HEEBO-FFPET for KEGG
biological pathways identified as relatively highly expressed in
DTF or SFT. Each enriched KEGG biological pathway is
indicated in column B, the numbers of genes from the pathway
differentially expressed in DTF or SFT is presented in column C,
the modified Fisher exact p-value (EASE score) for the enrichment
is presented in column D, and the genes from the pathway
identified as highly expressed in DTF or SFT are provided in
column E.
Found at: doi:10.1371/journal.pone.0008768.s006 (0.08 MB
DOC)
Table S5 Genes expressed exclusively (or almost exclusively) in
DTF or SFT. This list presents the 44 genes identified as
exclusively (or almost exclusively) expressed in SFT (A) or DTF (B)
in the analysis of the 3SEQ data. The criteria for inclusion on this
list was the gene must show at least 100 reads across the DTF or
SFT samples and be expressed exclusively in DTF or SFT or show
at least 100 fold increased expression in DTF or SFT.
Found at: doi:10.1371/journal.pone.0008768.s007 (0.07 MB
DOC)
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